Cancel
See Linkedin
Known information
- Has over 17 years of oncology clinical development experience across North America, Europe, Asia, and Australia.
- Grew the Precision Medicine TEPMETKO® Program globally and advanced research liquid biopsies to obtain 'Breakthrough Therapy Designation' by the FDA for Tepotinib (c-met inhibitor) NSCLC program.
- Winner of multiple leadership awards for creating and executing innovative customized solutions for speedy, efficient trial life cycles to achieve global milestones on time.
- Began career as a Program Manager at Selventa, a company discovering genetic pathways for drug-resistant solid tumors.
- Recruited by Memorial Sloan-Kettering to lead the Breast and Thoracic Oncology Unit as a Portfolio Manager.
- Managed a portfolio of over 75 clinical trials and a staff of more than 30 at Memorial Sloan-Kettering.
- Selected as the New York State leader for Cancer and Leukemia Group B (CALGB) national program.
- Served as Therapeutic Compound Lead and Executive Director for Iqvia and Syneos, managing the Tepotinib and Bavencio programs.
- Filed two INDs and established entire clinical operations departments at Relay and MetaboMed.
- Frequent ASCO poster presenter and guest speaker and panelist at many oncology conferences.
- Holds a bachelor's degree in Mathematics from the University of Mumbai.
- Completed a Pre-Medicine Diploma from Harvard University.
About Acrivon Therapeutics
Acrivon Therapeutics develops precision oncology medicines using a proprietary proteomics-based platform, with its lead candidate ACR-368 in a Phase 2 trial for multiple tumor types.
Report inaccurate information
